Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease

Michael Charlton, Pavla Kasparova, Shiobhan Weston, Keith Lindor, Yaakov Maor-Kendler, Russell H. Wiesner, Charles B. Rosen, Kenneth P. Batts

Research output: Contribution to journalArticle

228 Citations (Scopus)

Abstract

Although nonalcoholic steatohepatitis (NASH) has generally been considered a benign condition, the increasing prevalence and severity of obesity has heightened concerns about the frequency with which NASH progresses to end-stage liver disease. The aim of this study is to determine the frequency, clinical features, and posttransplantation history of decompensated liver disease secondary to NASH. The frequency of NASH as a cause of end-stage liver disease was prospectively determined in patients evaluated for liver transplantation. NASH was considered to be the primary cause of liver disease in patients who had histological evidence of steatohepatitis and in whom chronic liver diseases other than NASH were excluded. Posttransplantation histological characteristics were also determined in patients with NASH and compared with those of patients with pretransplantation diagnoses of cholestatic liver diseases, alcoholic disease, and hepatitis C. Of 1,207 patients evaluated for liver transplantation during the study period, 31 patients (2.6%) had NASH as the primary cause of liver disease. In the same period, 546 liver transplantations were performed, 16 of which (2.9%) were for end-stage disease secondary to NASH. Posttransplantation steatosis was seen in 60% of transplant recipients with NASH versus 5% of those with cholestatic disease, 15% of those with alcoholic disease, and 15% of those with hepatitis C. Steatohepatitis recurred in 33% of transplant recipients with NASH, with progression to cirrhosis in 12.5%. NASH can progress to end-stage liver disease in a minority of affected patients and was the primary cause of liver disease in 2.9% of patients evaluated for liver transplantation at our center. Recurrence of steatosis and NASH is frequent and can be severe after liver transplantation.

Original languageEnglish (US)
Pages (from-to)608-614
Number of pages7
JournalLiver Transplantation
Volume7
Issue number7
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Liver Diseases
Liver Transplantation
End Stage Liver Disease
Fatty Liver
Hepatitis C
Non-alcoholic Fatty Liver Disease
Alcoholic Hepatitis
Fibrosis
Chronic Disease
Obesity
Recurrence

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Charlton, M., Kasparova, P., Weston, S., Lindor, K., Maor-Kendler, Y., Wiesner, R. H., ... Batts, K. P. (2001). Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transplantation, 7(7), 608-614. https://doi.org/10.1053/jlts.2001.25453

Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. / Charlton, Michael; Kasparova, Pavla; Weston, Shiobhan; Lindor, Keith; Maor-Kendler, Yaakov; Wiesner, Russell H.; Rosen, Charles B.; Batts, Kenneth P.

In: Liver Transplantation, Vol. 7, No. 7, 2001, p. 608-614.

Research output: Contribution to journalArticle

Charlton, M, Kasparova, P, Weston, S, Lindor, K, Maor-Kendler, Y, Wiesner, RH, Rosen, CB & Batts, KP 2001, 'Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease', Liver Transplantation, vol. 7, no. 7, pp. 608-614. https://doi.org/10.1053/jlts.2001.25453
Charlton, Michael ; Kasparova, Pavla ; Weston, Shiobhan ; Lindor, Keith ; Maor-Kendler, Yaakov ; Wiesner, Russell H. ; Rosen, Charles B. ; Batts, Kenneth P. / Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. In: Liver Transplantation. 2001 ; Vol. 7, No. 7. pp. 608-614.
@article{f595dd98d9ca4d0aa90c863bb215d613,
title = "Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease",
abstract = "Although nonalcoholic steatohepatitis (NASH) has generally been considered a benign condition, the increasing prevalence and severity of obesity has heightened concerns about the frequency with which NASH progresses to end-stage liver disease. The aim of this study is to determine the frequency, clinical features, and posttransplantation history of decompensated liver disease secondary to NASH. The frequency of NASH as a cause of end-stage liver disease was prospectively determined in patients evaluated for liver transplantation. NASH was considered to be the primary cause of liver disease in patients who had histological evidence of steatohepatitis and in whom chronic liver diseases other than NASH were excluded. Posttransplantation histological characteristics were also determined in patients with NASH and compared with those of patients with pretransplantation diagnoses of cholestatic liver diseases, alcoholic disease, and hepatitis C. Of 1,207 patients evaluated for liver transplantation during the study period, 31 patients (2.6{\%}) had NASH as the primary cause of liver disease. In the same period, 546 liver transplantations were performed, 16 of which (2.9{\%}) were for end-stage disease secondary to NASH. Posttransplantation steatosis was seen in 60{\%} of transplant recipients with NASH versus 5{\%} of those with cholestatic disease, 15{\%} of those with alcoholic disease, and 15{\%} of those with hepatitis C. Steatohepatitis recurred in 33{\%} of transplant recipients with NASH, with progression to cirrhosis in 12.5{\%}. NASH can progress to end-stage liver disease in a minority of affected patients and was the primary cause of liver disease in 2.9{\%} of patients evaluated for liver transplantation at our center. Recurrence of steatosis and NASH is frequent and can be severe after liver transplantation.",
author = "Michael Charlton and Pavla Kasparova and Shiobhan Weston and Keith Lindor and Yaakov Maor-Kendler and Wiesner, {Russell H.} and Rosen, {Charles B.} and Batts, {Kenneth P.}",
year = "2001",
doi = "10.1053/jlts.2001.25453",
language = "English (US)",
volume = "7",
pages = "608--614",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease

AU - Charlton, Michael

AU - Kasparova, Pavla

AU - Weston, Shiobhan

AU - Lindor, Keith

AU - Maor-Kendler, Yaakov

AU - Wiesner, Russell H.

AU - Rosen, Charles B.

AU - Batts, Kenneth P.

PY - 2001

Y1 - 2001

N2 - Although nonalcoholic steatohepatitis (NASH) has generally been considered a benign condition, the increasing prevalence and severity of obesity has heightened concerns about the frequency with which NASH progresses to end-stage liver disease. The aim of this study is to determine the frequency, clinical features, and posttransplantation history of decompensated liver disease secondary to NASH. The frequency of NASH as a cause of end-stage liver disease was prospectively determined in patients evaluated for liver transplantation. NASH was considered to be the primary cause of liver disease in patients who had histological evidence of steatohepatitis and in whom chronic liver diseases other than NASH were excluded. Posttransplantation histological characteristics were also determined in patients with NASH and compared with those of patients with pretransplantation diagnoses of cholestatic liver diseases, alcoholic disease, and hepatitis C. Of 1,207 patients evaluated for liver transplantation during the study period, 31 patients (2.6%) had NASH as the primary cause of liver disease. In the same period, 546 liver transplantations were performed, 16 of which (2.9%) were for end-stage disease secondary to NASH. Posttransplantation steatosis was seen in 60% of transplant recipients with NASH versus 5% of those with cholestatic disease, 15% of those with alcoholic disease, and 15% of those with hepatitis C. Steatohepatitis recurred in 33% of transplant recipients with NASH, with progression to cirrhosis in 12.5%. NASH can progress to end-stage liver disease in a minority of affected patients and was the primary cause of liver disease in 2.9% of patients evaluated for liver transplantation at our center. Recurrence of steatosis and NASH is frequent and can be severe after liver transplantation.

AB - Although nonalcoholic steatohepatitis (NASH) has generally been considered a benign condition, the increasing prevalence and severity of obesity has heightened concerns about the frequency with which NASH progresses to end-stage liver disease. The aim of this study is to determine the frequency, clinical features, and posttransplantation history of decompensated liver disease secondary to NASH. The frequency of NASH as a cause of end-stage liver disease was prospectively determined in patients evaluated for liver transplantation. NASH was considered to be the primary cause of liver disease in patients who had histological evidence of steatohepatitis and in whom chronic liver diseases other than NASH were excluded. Posttransplantation histological characteristics were also determined in patients with NASH and compared with those of patients with pretransplantation diagnoses of cholestatic liver diseases, alcoholic disease, and hepatitis C. Of 1,207 patients evaluated for liver transplantation during the study period, 31 patients (2.6%) had NASH as the primary cause of liver disease. In the same period, 546 liver transplantations were performed, 16 of which (2.9%) were for end-stage disease secondary to NASH. Posttransplantation steatosis was seen in 60% of transplant recipients with NASH versus 5% of those with cholestatic disease, 15% of those with alcoholic disease, and 15% of those with hepatitis C. Steatohepatitis recurred in 33% of transplant recipients with NASH, with progression to cirrhosis in 12.5%. NASH can progress to end-stage liver disease in a minority of affected patients and was the primary cause of liver disease in 2.9% of patients evaluated for liver transplantation at our center. Recurrence of steatosis and NASH is frequent and can be severe after liver transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0034925012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034925012&partnerID=8YFLogxK

U2 - 10.1053/jlts.2001.25453

DO - 10.1053/jlts.2001.25453

M3 - Article

VL - 7

SP - 608

EP - 614

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 7

ER -